What is Immatics?
Immatics is dedicated to advancing cancer treatment through innovative immunotherapies. The company combines the discovery of crucial cancer targets with the development of precise T cell receptors to elicit a potent and specific T cell response. This expertise forms the bedrock of their pipeline, which includes Adoptive Cell Therapies and TCR Bispecifics. Immatics also engages in strategic partnerships with leading pharmaceutical entities, aiming to harness the power of T cells to unlock new therapeutic avenues for patients battling cancer.
How much funding has Immatics raised?
Immatics has raised a total of $392.5M across 8 funding rounds:
Series A
$9.9M
Series B
$52.1M
Series C
$71.2M
Series D
$16.3M
Other Financing Round
$30M
Other Financing Round
$58M
Share Placement
$35M
Private Equity
$120M
Series A (2004): $9.9M with participation from EMBL Ventures, Merifin Capital, 3i Group, and VINCI CAPITAL
Series B (2007): $52.1M led by DH Capital, NTEC, KfW, OH Beteiligungen, and 3i Group
Series C (2010): $71.2M supported by MIG Capital, AT Impf, and dievini Hopp Biotech Holding
Series D (2013): $16.3M featuring dievini Hopp BioTech, Wellington Partners, and MIG Funds
Other Financing Round (2017): $30M backed by Amgen
Other Financing Round (2017): $58M with participation from AT Impf, dievini Hopp Biotech Holding, and Amgen
Share Placement (2023): $35M led by Bristol-Myers Squibb
Private Equity (2023): $120M supported by Moderna
Key Investors in Immatics
dievini Hopp BioTech
dievini Hopp BioTech is an investor specializing in Life and Health Sciences, focusing on innovative therapeutic and diagnostic methods, particularly in oncology and cell therapy, with an emphasis on personalized medicine.
Wellington Partners
Wellington Partners is a European venture capital firm investing in early- and growth-stage life science companies, supporting entrepreneurs in developing breakthrough technologies in the health sector.
MIG Funds
MIG Capital is a Munich-based venture capital firm focused on startups in Life Sciences and Deep Tech, uniquely positioned as a retail venture capital investor in Germany.
What's next for Immatics?
The substantial enterprise-level backing and recent strategic investment position Immatics for accelerated growth and the further advancement of its therapeutic pipeline. With a focus on developing novel T cell-based treatments, the company is poised to make significant contributions to oncology. Future endeavors will likely involve expanding clinical trials, forging new strategic alliances, and potentially scaling manufacturing capabilities to meet the growing demand for advanced cancer immunotherapies. The company's commitment to innovation suggests a continued trajectory of development and market penetration in the biopharmaceutical sector.
See full Immatics company page
